Small ALS trial found no significant disease-progression difference

A phase II, randomised, placebo-controlled, double-blind trial of cannabis extract for amyotrophic lateral sclerosis: the EMERALD trial.

BMJ neurology open • • Highly Relevant
🤖

AI Summary

The EMERALD trial asked whether a cannabis-based medicine extract could affect disease progression in people with amyotrophic lateral sclerosis (ALS). In this randomised, double-blind, placebo-controlled trial, 17 participants were assigned to extract or placebo for 6 months, but only 8 completed treatment. The primary outcome, the ALS Functional Rating Scale-Revised score at treatment end, did not differ significantly between groups; the trial also found no significant differences in its secondary outcomes.

Exploratory analyses suggested possible effects on pain and cognition, including a statistically significant executive-function result, but the other reported pain and memory comparisons were not statistically significant. These small-sample findings are tentative and need confirmation. Because recruitment fell short of the target and the study was underpowered, this abstract cannot establish whether the extract slows ALS progression or reliably improves symptoms; this is an abstract-based summary.

💡 Key Findings

1
At treatment end, the primary ALSFRS-R outcome showed no significant difference between cannabis extract and placebo.
High
95%
2
The trial was underpowered: 17 participants enrolled and 8 completed treatment, limiting its ability to detect an effect on ALS progression.
High
98%
3
Exploratory analyses found a statistically significant executive-function result, alongside possible pain and memory signals; these small-sample findings require confirmation.
High
90%

📄 Original Abstract

INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited disease-modifying treatment options. Preclinical and clinical data suggest that cannabinoid-based therapies may exert neuroprotective and symptomatic benefits. We conducted a trial to evaluate the effects of cannabis-based medicine extract (CBME) on disease progression in patients with ALS. METHODS: This was a randomised, double-blind, placebo-controlled trial. Participants received CBME or placebo for 6 months. The primary outcome was the difference in ALS Functional Rating Scale-Revised (ALSFRS-R) scores at the end of treatment (EOT). Secondary outcomes included adverse events, forced vital capacity (FVC), pain and spasticity measures, weight loss, cognition and quality of life. RESULTS: Due to COVID-19 restrictions and driving limitations, only 17 participants were enrolled (CBME: n=8; placebo: n=9), and 8 completed treatment (4 per group). At EOT, adjusted mean ALSFRS-R scores were 31.67 for CBME and 34.33 for placebo (difference: -2.66; 95% CI -7.25 to 1.92; p=0.18; n=8). No significant differences were observed in secondary outcomes. Post hoc analyses suggested potential effects of CBME on pain and cognition for further confirmation: usual pain intensity decreased by 2.52 points (95% CI -8.92 to 3.87, p=0.34; n=8), a decrease of 3 days in the number of pain days (95% CI -28.90 to 22.59, p=0.75; n=8), executive function improved by 7.71 points (95% CI 0.90 to 14.52; p=0.04; n=8) and a 5.68-point improvement in memory (95% CI -0.29 to 11.64; p=0.06; n=8). CONCLUSION: This trial did not achieve the target sample size therefore was underpowered to demonstrate efficacy of cannabis in slowing ALS progression. However, exploratory analyses generated hypotheses regarding possible effects on pain and cognition which require confirmation in adequately powered studies. TRIAL REGISTRATION NUMBER: (ID: NCT03690791) on 27 September 2018.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.